Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study

Olivia V Swann,1,2 Karl A Holden,3,4 Lance Turtle,5,6 Louisa Pollock,7 Cameron J Fairfield,8 Thomas M Drake,8 Sohan Seth,9 Conor Egan,9 Hayley E Hardwick,5 Sophie Halpin,10 Michelle Girvan,10 Chloe Donohue,10 Mark Pritchard,11 Latifa B Patel,12 Shamez Ladhani,13,14 Louise Sigfrid,15 Ian P Sinha,3,12 Piero L Olliaro,15 Jonathan S Nguyen-Van-Tam,16,17 Peter W Horby,15 Laura Merson,15 Gail Carson,15 Jake Dunning,18,19 Peter J M Openshaw,19 J Kenneth Baillie20,21 Ewen M Harrison,8 Annemarie B Docherty,8,21 Malcolm G Semple,4,5 On behalf of ISARIC4C Investigators

ABSTRACT

OBJECTIVE
To characterise the clinical features of children and young people admitted to hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK and explore factors associated with admission to critical care, mortality, and development of multisystem inflammatory syndrome in children and adolescents temporarily related to coronavirus disease 2019 (covid-19) (MIS-C).

DESIGN
Prospective observational cohort study with rapid data gathering and near real time analysis.

SETTING
260 hospitals in England, Wales, and Scotland between 17 January and 3 July 2020, with a minimum follow-up time of two weeks (to 17 July 2020).

PARTICIPANTS
651 children and young people aged less than 19 years admitted to 138 hospitals and enrolled into the International Severe Acute Respiratory and emergency Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK study with laboratory confirmed SARS-CoV-2.

WHAT IS ALREADY KNOWN ON THIS TOPIC
Less information on ethnicity, comorbidities, and clinical and laboratory findings is available in children with SARS-CoV-2 than in adults
A multisystem inflammatory syndrome in children and adolescents (MIS-C) temporally associated with SARS-CoV-2 has been widely reported
However, all reports to date arise from retrospective cases series that are vulnerable to ascertainment, selection, and recall bias

WHAT THIS STUDY ADDS
Severe disease was rare and death exceptionally rare in this is a large prospective cohort study of children admitted to hospital with laboratory confirmed covid-19
Ethnicity seems to be a factor in both critical care admission and MIS-C
This cohort has enabled identification of additional clinical and laboratory characteristics that should help to refine the WHO criteria for MIS-C

MAIN OUTCOME MEASURES
Admission to critical care (high dependency or intensive care), in-hospital mortality, or meeting the WHO preliminary case definition for MIS-C.

RESULTS
Median age was 4.6 (interquartile range 0.3-13.7) years, 35% (225/651) were under 12 months old, and 56% (367/650) were male. 57% (330/576) were white, 12% (67/576) South Asian, and 10% (56/576) black. 42% (276/651) had at least one comorbidity. 11% (52/456) met the WHO MIS-C criteria, with the first patient developing symptoms in mid-March. Children meeting MIS-C had profound comorbidity. 11% (52/456) met the WHO MIS-C criteria, with the first patient developing symptoms in mid-March. Children meeting MIS-C criteria were older (median age 10.7 (8.3-14.1) years; P<0.001) than children who did not have MIS-C. No deaths occurred in the MIS-C group.

CONCLUSIONS
Children and young people have less severe acute covid-19 than adults. A systemic mucocutaneous-enteric cluster of symptoms was identified, which encompassed the symptoms for the WHO MIS-C criteria. 18% (116/632) of children were admitted to critical care. On multivariable analysis, this was associated with age under 1 month (odds ratio 3.21, 95% confidence interval 1.6 to 6.6; P=0.008), age 10-14 years (3.23, 1.55 to 6.99; P=0.002), and black ethnicity (2.82, 1.55 to 5.57; P=0.003). Six (1%) of 627 patients died in hospital, all of whom had profound comorbidity. 11% (52/456) met the WHO MIS-C criteria, with the first patient developing symptoms in mid-March. Children meeting MIS-C criteria were older (median age 10.7 (8.3-14.1) years; P=0.001) and more likely to be of non-white ethnicity (64% (29/45) v 4% (1/26); P=0.004). Children with MIS-C were five times more likely to be admitted to critical care (73% (38/52) v 15% (62/404); P<0.001). In addition to the WHO criteria, children with MIS-C were more likely to present with fatigue (51% (24/47) v 28% (86/302); P=0.004), headache (34% (16/47) v 10% (26/263); P<0.001), myalgia (34% (15/44) v 8% (21/270); P<0.001), sore throat (30% (14/47) v 12% (34/284); P=0.003), and lymphadenopathy (20% (9/46) v 3% (10/318); P<0.001) and to have a platelet count of less than 150 × 109/L (32% (16/50)) v 3% (3/120); P<0.001) than children who did not have MIS-C. No deaths occurred in the MIS-C group.
the MIS-C criteria have different demographic and clinical features depending on whether they have acute SARS-CoV-2 infection (polymerase chain reaction positive) or are post-acute (antibody positive).

**STUDY REGISTRATION**
ISRCTN66726260.

**Introduction**
Children and young people comprise only 1-2% of cases of coronavirus disease 2019 (covid-19) worldwide.1,2 In contrast to other respiratory viruses, children seem to have a lower risk of infection than adults,3 and the vast majority of reported infections in children are mild or asymptomatic, with few recorded childhood fatalities attributed to covid-19.4-7 Initial reports from China showed that only 0.6% of children with covid-19 were critically ill.5

A severe disease phenotype has emerged in children that seems to be temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.8 9 The condition was first described in May 2020 in a cluster of children admitted to critical care in south London (UK), with evidence of a multisystem hyperinflammatory state with features similar to Kawasaki disease and toxic shock syndrome.8 These children needed inotropic support for refractory circulatory shock and mechanical ventilation for cardiovascular stabilisation rather than respiratory failure. Similar cohorts have been reported in Italy and France.10 11 The European Centre for Disease Prevention and Control estimated on 15 May 2020 that around 230 children had presented with this new syndrome in EU/EEA countries, with two fatalities.3 The World Health Organization and the Royal College of Paediatrics and Child Health (RCPCH) have proposed preliminary case definitions.9 12 WHO uses the term multisystem inflammatory syndrome in children and adolescents temporarily related to covid-19 (MIS-C), and the RCPCH describes this illness as paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS).

We aimed to characterise the features of children and young people (aged <19 years) admitted to hospital in the UK with laboratory confirmed SARS-CoV-2 infection from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) cohort. As our study enrolled patients prospectively from the beginning of the pandemic, we also had a unique opportunity to examine the emergence, timing, risk factors, clinical presentation, progression, course, and outcomes of children and young people meeting the WHO preliminary case definition for MIS-C.9

**Methods**
**Study design and setting**
The ISARIC WHO CCP-UK is an ongoing prospective cohort study across acute care hospitals in England, Wales, and Scotland.13 This standing protocol for studying disease caused by pathogens of public health interest was activated on 17 January 2020. The protocol, associated documents, and details of the Independent Data and Material Access Committee (IDAMAC) are available at https://isaric4c.net. We used STROBE guidelines when reporting.

**Participants**
Patients of any age admitted to hospital with proven or high likelihood of SARS-CoV-2 infection were enrolled into the ISARIC WHO CCP-UK cohort as previously described.13 We present the data from children and young people aged less than 19 years on the date of hospital admission, enrolled into the study up to and including 3 July 2020, who had at least two weeks of outcome data available. For this report, we included only those children and young people who had documented laboratory evidence of SARS-CoV-2 infection (by polymerase chain reaction or serology). Patients were admitted to hospital or critical care at the discretion of the clinical team caring for them, and we set no criteria for these. We also included patients who were already admitted for other clinical reasons and subsequently tested positive for SARS-CoV-2 while an inpatient.

**Data collection**
Demographic and baseline data (including comorbidities and regular medications taken) alongside data on symptoms, clinical signs (including vital signs) during admission, laboratory and pathology investigations, treatments received while admitted, and outcome were collected onto case report forms (see supplementary methods). Data on illness progression and severity, including location within the hospital (ward versus critical care), were collected on day 1 (admission/diagnosis), day 3, day 6, day 9, admission to critical care, and discharge/death. Data were collected from healthcare records onto the case report forms through a secure online database, REDCap (Research Electronic Data Capture, Vanderbilt University, hosted by the University of Oxford). Collection of this routine anonymised demographic and clinical data from medical records did not require consent in England and Wales. In Scotland, a waiver for consent was obtained from the Public Benefit and Privacy Panel.

**Variables**
The case report form was agnostic to patients’ age, so existing comorbidity variables were not tailored to the paediatric population (see supplementary methods for case report form and recoding of paediatric variables). Ethnicity was self-reported and transcribed from the healthcare record. The Paediatric Early Warning Score (PEWS) was used as a measure of disease severity at admission.14

**Criteria for diagnosis of MIS-C**
We used the WHO preliminary case definition for MIS-C as a framework for identifying children with the
Box 1: WHO preliminary case definition for MIS-C, with adaptations (italics) defining thresholds to allow case identification in ISARIC WHO CCP-UK cohort

1. Fever for 3 days or more (of any duration, self-reported before presentation)
2. Plus two of the following:
   a. Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammatory signs (self-reported rash/conjunctivitis)
   b. Hypotension or shock (age <2 years, systolic blood pressure <60 mm Hg; ≥2 and <5 years, <70 mm Hg; ≥5 and <12 years, <80 mm Hg; ≥12 years, <90 mm Hg at any point in admission⁹)
   c. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (diagnosis of endocarditis or myocarditis or documented pericardial effusion, coronary artery aneurysm, cardiomegaly, or cardiac dysfunction on echocardiography)
   d. Evidence of coagulopathy (international normalised ratio >1.2 (any age), premature neonate with prothrombin time >16 s¹⁵ or term infant/older child with prothrombin time >14 s¹⁶¹⁷ (see supplementary methods))
   e. Acute gastrointestinal problems (self-reported diarrhoea, vomiting, or abdominal pain)
3. Plus elevated markers of inflammation (C reactive protein ≥60 mg/L or ferritin ≥200 mg/L at any point during admission; cut-offs chosen after expert discussion)
4. Plus no other obvious microbial cause of inflammation (no significant positive growth on blood culture/cerebrospinal fluid culture during admission)

syndrome within this dataset (box 1),⁹ with adaptations defining thresholds to allow case identification in the ISARIC WHO CCP-UK cohort.

Duplicates
For cases in which a child appeared twice in the dataset (that is, by readmission or transfer between two recruiting centres), we retained only one admission in the data (detailed in supplementary methods).

Outcomes
The primary outcomes of this study were admission to critical care (high dependency unit or paediatric intensive care unit), development of MIS-C, and in-hospital mortality. Paediatric intensive care units are dedicated care settings providing the highest level of critical care for children and young people, who usually need invasive ventilation or support for two or more organs with a higher nurse to patient ratio. Paediatric intensive care units are usually located in regional tertiary centres or specialised hospitals. Paediatric high dependency units are for patients needing close monitoring and therapies for organ support without invasive ventilation or intensive care and are provided at tertiary hospitals and a limited number of district general hospitals.¹⁷ Admission to critical care is governed by the degree of physiological instability rather than diagnosis. We also examined need for respiratory and cardiovascular support. A minimum two week follow-up was ensured for all included patients.

Bias and missing data
Specialist children’s hospitals (tertiary care) with paediatric specific research teams and paediatric intensive care units may be over-represented. Capacity to enrol was also limited by staff resources at times of high covid-19 activity, and we were unable to comment on patients who were not recruited.

The pandemic disrupted routine care and usual research activities, limiting data collection and verification, particularly during the peak of outbreak activity. We did not impute missing data for this descriptive analysis. To reduce the effect of missing data on outcome analyses, we restricted these analyses to patients who had been admitted for at least two weeks before data extraction. Complete data were not available for all variables, so denominators differ between analyses.

Statistical analysis
Continuous variables are shown as mean (standard deviation) or as median (interquartile range) if non-normally distributed. Categorical variables are presented as a frequency (percentage) unless otherwise stated. For univariable comparisons, we used Welch’s t, analysis of variance, Mann-Whitney U, or Kruskal-Wallis tests, according to data distribution. We compared categorical data by using χ² tests and considered a P value below 0.05 to be statistically significant; all tests were two sided. We made no adjustment for multiple comparisons. Parsimonious criterion based model building used the following principles: relevant explanatory variables were identified from previous studies; interactions were checked at first order level; final model selection was informed by the Akaike information criterion and C statistic, with appropriate assumptions checked including the distribution of residuals. Analysis of symptom co-occurrence used the Jaccard similarity coefficient and was presented as a hierarchically ordered heatmap (supplementary methods). We used R (R Core Team version 3.6.3, Vienna, Austria) for statistical analyses, with packages including tidyverse, finalfit, lubridate, ggplot2, gplot, mclust, dendextend, and UpSetR.

Patient and public involvement
This was an urgent public health research study in response to a public health emergency of international concern. Patients and the public were not involved in the design, conduct, or reporting of this rapid response research.

Results
Between 17 January and 3 July 2020, 69 516 patients of all ages (range 0-106 years) were enrolled at 260 hospitals across England, Scotland, and Wales. Of these, 651 were patients under 19 years old with laboratory confirmed SARS-CoV-2 (651/69 516 (0.9%) of the total cohort (table 1; supplementary figures A and B). These patients were enrolled across 138 sites, of which 20 had a paediatric intensive care unit. We recruited 55 patients as hospital inpatients; they had been admitted for more than five days before symptom onset, indicating likely hospital acquired infection.
The median age of the children was 4.6 (interquartile range 0.3-13.7) years, 35% (225/651) were under 12 months old, and 56% (367/650) were male (table 1). Ethnicity was recorded in 88% (576/651) of cases: 57% (330/576) were white, 12% (67/576) were South Asian, and 10% (56/576) were of black ethnicity. At least one comorbidity was reported in 42% (276/651) of cases.

Symptoms

The most common presenting symptoms were fever (70%; 431/617), cough (39%; 233/599), nausea/vomiting (32%; 179/564), and shortness of breath (30%; 173/570) (fig 1). Fever and rhinorrhea were less common with increasing age; however, nausea and vomiting, abdominal pain, headache, and sore throat showed an increasing trend with age (supplementary figure D). A heatmap and dendrogram of presenting symptoms showed three distinct clusters of clinical phenotypes (fig 2). These comprised most commonly a discrete respiratory illness (green cluster) of cough, fever, shortness of breath, runny nose, lower chest wall indrawing, and wheeze, with clustering of both upper and lower respiratory symptoms together. Next was a cluster representing a systemic mucocutaneous-enteric illness (purple cluster) of headache, myalgia, sore throat, vomiting, abdominal pain, diarrhea, fatigue, rash, lymphadenopathy, and conjunctivitis. Finally, we observed a rarer neurological cluster of seizures and confusion (red cluster). The systemic mucocutaneous-enteric cluster includes the symptoms specified in the WHO preliminary case definition for MIS-C ("muco-cutaneous inflammation" and "acute gastrointestinal problems"), in addition to sore throat, myalgia, headache, and fatigue. The two main clusters “respiratory” and “systemic mucocutaneous-enteric” were not entirely dichotomous. Minor overlap occurred between a sub-cluster of “fever, cough, and shortness of breath” and a sub-cluster of “vomiting, abdominal pain, diarrhea, fatigue, and rash” but very little overlap with “runny nose, wheeze, and lower chest wall indrawing.”

Comorbidities

The most common comorbidities were neurological (11%; 65/614), haematological/oncological/immunological (combined category as described in supplementary methods: 8%; 48/615), and asthma (7%; 45/615). Data on prematurity (defined as birth before completion of 37 weeks’ gestation) were as usual routinely collected only for children aged under 1 year, and 23% (46/201) were premature (table 1, supplementary table A, and supplementary figure C). The median PEWS at presentation was 3 (interquartile range 1.0-5.0), and median blood test results at presentation were mostly within normal ranges (supplementary tables B and C). Antibiotics were given to 69% (415/601) of children, and 6% (38/591) received antiviral drugs (30 received acyclovir, 7 received remdesivir, and 3 received chloroquine/hydroxychloroquine, some in combination) (table 2).

Children needing critical care

Eighteen per cent (116/632) of children were admitted to critical care (intensive care unit or high dependency unit level care); 8% (47/597) received inotropic support, 9% (57/619) received non-invasive ventilation, and 9% (58/620) received invasive mechanical ventilation (table 2, table 3, and supplementary figure E). Black ethnicity was significantly associated with admission to critical care on multivariable analysis (odds ratio 2.82, 95% confidence interval 1.41 to 5.57; P=0.003) (table 4 and supplementary table D). On multivariable analysis, both age under 1 month (odds ratio 3.21, 1.36 to 7.66; P=0.008) and age between 10 and 14 years (3.23, 1.55 to 6.99; P=0.002) were associated with increased odds of admission to critical care.

Table 1 | Demographics across cohort of patients under 19 years with laboratory confirmation of SARS-CoV-2. Values are numbers (percentages) unless stated otherwise

| Variable | Patients (n=651) |
|----------|----------------|
| Median (interquartile range) age, years | 4.6 (0.3-13.7) |
| Age group: | |
| <1 month | 53 (8.1) |
| 1 month to <1 year | 172 (26.4) |
| 1-4 years | 108 (16.6) |
| 5-9 years | 92 (14.1) |
| 10-14 years | 94 (14.6) |
| 15-19 years | 132 (20.3) |
| Sex at birth: | |
| Male | 367 (56.4) |
| Female | 283 (43.5) |
| Missing | 1 (0.2) |
| Ethnicity: | |
| White | 330 (50.7) |
| Black | 56 (8.6) |
| South Asian | 67 (10.3) |
| Other | 123 (18.9) |
| Missing | 75 (11.5) |
| Admitted >5 days before symptom onset: | |
| No | 538 (82.6) |
| Yes | 55 (8.4) |
| Missing | 58 (8.9) |
| Any comorbidity: | |
| No/unknown | 375 (57.6) |
| Yes | 276 (42.4) |
| Neurological comorbidity: | |
| No | 549 (84.3) |
| Yes | 65 (10.0) |
| Missing | 37 (5.7) |
| Haematological, oncological, immunological comorbidity: | |
| No | 567 (87.1) |
| Yes | 48 (7.4) |
| Missing | 36 (5.5) |
| Asthma: | |
| No | 570 (87.6) |
| Yes | 45 (6.9) |
| Missing | 36 (5.5) |
| Prematurity*: | |
| No | 155 (23.8) |
| Yes | 46 (7.1) |
| Missing | 450 (69.1) |
| Immunosuppressant use before presentation†: | |
| No | 546 (83.9) |
| Yes | 53 (8.1) |
| Missing | 52 (8.0) |

*Defined as birth before completion of 37 weeks’ gestation. †Includes oral but not inhaled corticosteroids.

Age, sex, and ethnicity

The median age of the children was 4.6 (interquartile range 0.3-13.7) years, 35% (225/651) were under 12 months old, and 56% (367/650) were male (table 1). Ethnicity was recorded in 88% (576/651) of cases: 57% (330/576) were white, 12% (67/576) were South Asian, and 10% (56/576) were of black ethnicity. At least one comorbidity was reported in 42% (276/651) of cases.
with admission to critical care (reference age group 15-19 years), but we found no association with sex on either univariable or multivariable analysis (table 3, table 4, and supplementary table D).

On univariable analysis, children with comorbidities were more likely to be admitted to critical care than those without comorbidities (odds ratio 1.73, 1.15 to 2.60; P=0.008); however, this no longer reached significance in the multivariable model (odds ratio 1.42, 0.89 to 2.28; P=0.141). Comorbidities most commonly associated with critical care admission on univariable analysis were prematurity (50% (15/30) of critical care admissions v 18% (30/165) of standard care admissions; P=0.001), respiratory comorbidities (10% (12/115) v 4% (21/491); P=0.019), cardiac comorbidities (13/115 (11%) v 25/493 (5%); P=0.018), and obesity (6% (7/115) v 2% (10/487); P=0.028) (table 3 and supplementary table E). Children receiving critical care were more likely to have been admitted to hospital more than five days before their symptoms started (indicating likely hospital acquired infection) than those receiving ward level care (16% (18/110) v 8% (36/473); P=0.009). We found no association between previous immunosuppressant use and critical care admission (table 3).

Children admitted to critical care were more likely to have presented with diarrhoea, (38% (40/104) v 13% (58/448); P<0.001), conjunctivitis (16% (16/100) v 2% (10/412); P=0.001), and altered consciousness/confusion (19% (19/99) v 6% (26/434); P<0.001) than those cared for on a standard ward (supplementary table F). They were objectively more unwell at presentation than those receiving standard ward care (median PEWS of 5 (2.0-7.0) v 2 (1.0-4.0); P=0.001) (supplementary table G). We also observed significant differences in haematological, biochemical, and radiological abnormalities between the two groups at presentation (supplementary table H). In particular, children admitted to critical care had a lower platelet count (median 192.0×10^9/L (interquartile range 133.0-280.5×10^9/L) v 296.5×10^9/L (229.0-383.5×10^9/L); P=0.001), a higher neutrophil count (7.7×10^9/L (4.3-12.3×10^9/L) v 4.6×10^9/L (2.3-8.2×10^9/L); P<0.001), and higher C reactive protein (64.5 (11.1-200.2) mg/L v 11.0 (3.0-54.5) mg/L; P<0.001) at presentation than those cared for on a standard ward. Children admitted to critical care were also more likely to have infiltrates on a chest radiograph (58% (47/81) v 32% (52/162); P<0.001).

We did a sub-analysis for critical care admission excluding any children who met the criteria for MIS-C. In this subgroup, the associations described above persisted, although obesity was no longer significantly associated with critical care admission (supplementary table I). In patients without MIS-C, prematurity and respiratory and cardiac comorbidities remained significantly associated with admission to critical care (22% (17/77) v 10% (46/481); P=0.003), neurodisability (13% (9/71) v 5% (22/463); P=0.014), and gastrointestinal (9% (7/77) v 2% (11/480); P=0.007) comorbidities (supplementary table J), as is generally the case for children and young people most at risk of admission to critical care. After exclusion of children with MIS-C, conjunctivitis and diarrhoea were no longer significantly associated with critical care admission (supplementary table K); instead, shortness of breath (44% (31/71) v 28% (123/445); P=0.008) was associated with critical care admission. Total PEWS at presentation remained associated with critical care admission (supplementary table L). As expected, when cases of MIS-C were excluded, blood tests in patients admitted to critical care were generally more unwell (supplementary table M). In particular, children admitted to critical care had a lower platelet count (median 192.0×10^9/L (interquartile range 133.0-280.5×10^9/L) v 296.5×10^9/L (229.0-383.5×10^9/L); P=0.001), a higher neutrophil count (7.7×10^9/L (4.3-12.3×10^9/L) v 4.6×10^9/L (2.3-8.2×10^9/L); P<0.001), and higher C reactive protein (64.5 (11.1-200.2) mg/L v 11.0 (3.0-54.5) mg/L; P<0.001) at presentation than those cared for on a standard ward.
care showed less of an inflammatory pattern compared with those cared for on a standard ward (median neutrophils $6.2\times10^9/L$ (3.4-9.6$\times10^9/L$) in critical care admissions versus $4.5\times10^9/L$ (2.3-8.2$\times10^9/L$) in standard ward admissions ($P=0.059$) and median C reactive protein 21.4 (5.0-51.9) mg/L versus 9.0 (3.0-46.9) mg/L ($P=0.069$)) (supplementary table M).

### Outcomes
Outcome data were available for 627 children (table 2). Six (1%) children and young people died in hospital. Three were neonates (age <28 days) with severe comorbidities/illness—very premature, complex congenital cardiac anomaly, and bacterial sepsis. Three were aged 15-18 years, two of whom had profound neurodisability with pre-existing respiratory compromise; the other was immunosuppressed by chemotherapy for malignancy and had bacterial sepsis. Two children under 5 years old, both with life limiting, complex comorbidities, were discharged with planned palliative care and cause of death was not related to covid-19. Eighty nine per cent (557/627) of children and young people were discharged alive, and 10% (62/627) continued to receive care at the date of reporting (table 2).

### Patients meeting WHO preliminary case definition for MIS-C
Eleven per cent (52/456) of children met the WHO preliminary case definition for MIS-C (table 5 and supplementary figure F). The first patient identified developed symptoms in mid-March, when covid-19 cases were increasing nationally, followed by a small number of cases identified steadily throughout the surveillance period (fig 3). Geographically, the highest number of children with MIS-C came from areas with the largest covid-19 outbreaks—namely, the Midlands and Greater London (supplementary figure G).

Children who met the WHO preliminary definition for MIS-C were significantly older than those who did not.
not (median age 10.7 (8.3-14.1) v 1.6 (0.2-12.9) years; P<0.001) and were significantly more likely to be of non-white ethnicity (64% (29/45) v 42% (148/355); P=0.004) (table 5). MIS-C was associated with obesity (10% (5/51) v 2% (6/385); P=0.005) but not with any other comorbidity (supplementary table N). No children with MIS-C were admitted more than five days before symptom onset (table 5). In addition to the WHO preliminary case definition features (fever, rash, conjunctivitis, and gastrointestinal symptoms), the children with MIS-C were also more likely to present with fatigue (51% (24/47) v 28% (86/302); P=0.004), headache (34% (16/47) v 10% (26/263); P<0.001), myalgia (34% (15/44) v 8% (21/270); P<0.001), sore throat (30% (14/47) v 12% (34/284); P=0.003), and lymphadenopathy (20% (9/46) v 3% (10/318); P<0.001) than were children who did not meet MIS-C criteria (supplementary table O). Children with MIS-C also had a higher PEWS at presentation (median 5.0 (2.8-6.2) v 3.0 (1.0-5.0); P<0.001) and were more likely to have reduced consciousness (25% (13/51) v 9% (33/350); P=0.001) than those who did not meet the criteria (supplementary table P and supplementary figure H).

Children with MIS-C were five times more likely than others to be admitted to critical care (73% (38/52) v 15% (62/404); P<0.001) (table 5). They were more likely to receive intravenous corticosteroids (55% (24/44) v 6% (20/353); P<0.001), non-invasive (35% (18/52) v 8% (31/397); P<0.001) and invasive ventilation (27% (14/52) v 9% (36/397); P<0.001), and inotropic support (51% (25/49) v 9% (36/397); P=0.001) (table 5). Sixty five per cent (28/43) of patients with MIS-C received intravenous immunoglobulins, and 17% (7/42) received immunomodulatory therapy (three received anakinra, one tocilizumab, one adalimumab, one infliximab, and one unspecified) (supplementary table R). Fifty seven per cent (21/37) of MIS-C cases had one or more documented cardiac complications. Of these, 10 had impaired cardiac function on echocardiogram, nine had a pericardial effusion, three had electrocardiographic changes (heart block, junctional rhythm and T wave inversion, borderline ST elevation and changes of pericarditis), three had coronary artery dilatation, two had coronary artery aneurysm, two had myocarditis and two had valvular regurgitation. No deaths occurred in the MIS-C group.

Review of laboratory investigations found that children who met the criteria for MIS-C were more likely to have a platelet count of less than 150×10^9/L than those who did not (32% (16/50) v 11% (38/348); P<0.001) (supplementary table Q). Children who met the MIS-C criteria also had lower lymphocyte counts (median 0.9×10^9/L (0.7-1.7×10^9/L) v 2.2×10^9/L (1.3-3.8×10^9/L); P<0.001) but higher neutrophil counts (8.3×10^9/L (5.9-12.4×10^9/L) v 4.6×10^9/L (2.3-8.6×10^9/L); P=0.001) and higher creatinine (55.0 (35.8-82.5) μmol/L v 30.0 (20.0-51.8) μmol/L; P<0.001) than those without (supplementary table Q).

Of the 52 patients with MIS-C, 56% (28/50) were polymerase chain reaction positive for SARS-CoV-2 (acute infection), 44% (22/50) were SARS-CoV-2 antibody positive (post-acute), and two were confirmed but the method was not specified. (supplementary
Patients with MIS-C who were antibody positive were younger (median age 10.0 (7.7-13.2) years v 12.4 (8.9-15.3) years; P=0.057) and more likely to be of non-white ethnicity (90% (19/21) v 45% (10/22); P=0.003) than those who were polymerase chain reaction positive. Although obesity had been associated with MIS-C (table 5), when analysed by SARS-CoV-2 detection method this feature seemed to be driven by those with MIS-C who were polymerase chain reaction positive, as none of the antibody positive patients were obese (19% (5/27) v 0% (0/22); P=0.056) (supplementary table S).

On comparing presenting symptoms, we found that conjunctivitis (71% (15/21) v 16% (4/25); P<0.001) and abdominal pain (95% (20/21) v 44% (12/27); P<0.001) were more common in patients who were in the antibody positive group, whereas those in the acute phase of infection and positive by polymerase chain reaction were more likely to present with shortness of breath (52% (14/27) v 14% (3/21); P=0.014) (supplementary table T).
presentation (40% (10/25) v 14% (3/22); P=0.056) (supplementary table U). Blood results at presentation were similar between the two groups, with the exception of prothrombin time, which was longer in the group who were polymerase chain reaction positive (median 14.8 (13.4-15.8) sec v 11.6 (11.0-12.0) sec; P=0.013) (supplementary table V).

Treatments received also differed between the two groups, with patients who were antibody positive being more likely to receive intravenous steroids (84% (16/19) v 35% (8/23); P=0.002) and intravenous immunoglobulin (86% (19/22) v 43% (9/21); P=0.004) than those who were polymerase chain reaction positive (supplementary table R). The need for critical care or respiratory or cardiovascular support did not differ between the two groups. Although cardiac complications were seen in both groups, they were more frequent in patients with MIS-C who were antibody positive (75% (15/20) v 35% (6/17); P=0.022) (supplementary table R).

Discussion

Six hundred and fifty one children and young people aged under 19 years with laboratory confirmed SARS-CoV-2 were recruited to the ISARIC WHO CCP-UK study between 17 January and 3 July 2020, accounting for 0.9% of all patients in the whole cohort at that time. The median age of children with covid-19 was 4.6 (interquartile range 0.3–13.7) years. The cohort was predominantly male (56%) and of white ethnicity (57%), with most (58%) children having no known comorbidities. The most common presenting symptoms were fever, cough, shortness of breath, nausea, and vomiting, and a systemic mucocutaneous-enteric cluster of symptoms was seen. Eighteen per cent of children and a systemic mucocutaneous-enteric cluster of symptoms was seen. Eighteen per cent of children and a systemic mucocutaneous-enteric cluster of symptoms was seen. Eighteen per cent of children and a systemic mucocutaneous-enteric cluster of symptoms was seen. Eighteen per cent of children and a systemic mucocutaneous-enteric cluster of symptoms was seen. Eighteen per cent of children and a systemic mucocutaneous-enteric cluster of symptoms was seen.

Table 4 | Factors associated with admission to critical care unit. Values are numbers (percentages) unless stated otherwise

| Variable                  | Standard ward admission (n=516; 81.6%) | Critical care admission (n=116; 18.4%) | Univariable Odds ratio (95% CI) | Multivariable Odds ratio (95% CI) |
|---------------------------|---------------------------------------|---------------------------------------|---------------------------------|---------------------------------|
| Sex at birth:             |                                       |                                       |                                 |                                 |
| Male                      | 286 (80.1)                            | 71 (19.9)                             | -                               | -                               |
| Female                    | 229 (83.6)                            | 45 (16.4)                             | 0.79 (0.52 to 1.19); P=0.266     | 0.82 (0.51 to 1.31); P=0.405     |
| Age group:                |                                       |                                       |                                 |                                 |
| <1 month                  | 34 (66.7)                             | 17 (33.3)                             | 2.87 (1.34 to 6.16); P=0.007     | 3.21 (1.36 to 7.66); P=0.008     |
| 1 month to <1 year        | 152 (91.6)                            | 14 (8.4)                              | 0.53 (0.25 to 1.09); P=0.088     | 0.53 (0.27 to 1.25); P=0.151     |
| 1-4 years                 | 89 (85.6)                             | 15 (14.4)                             | 0.97 (0.46 to 2.01); P=0.938     | 1.28 (0.57 to 2.89); P=0.545     |
| 5-9 years                 | 73 (80.2)                             | 18 (19.8)                             | 1.41 (0.69 to 2.89); P=0.338     | 1.33 (0.58 to 3.05); P=0.493     |
| 10-14 years               | 58 (63.7)                             | 33 (36.3)                             | 3.26 (1.72 to 6.33); P=0.001     | 3.23 (1.55 to 6.99); P=0.002     |
| Ethnicity:                |                                       |                                       |                                 |                                 |
| White                     | 281 (87.3)                            | 41 (12.7)                             | -                               | -                               |
| Black                     | 36 (65.5)                             | 19 (34.5)                             | 3.62 (1.88 to 6.86); P=0.001     | 2.82 (1.41 to 5.57); P=0.003     |
| South Asian               | 49 (79.0)                             | 13 (21.0)                             | 1.82 (0.88 to 3.56); P=0.091     | 1.86 (0.87 to 3.77); P=0.094     |
| Other                     | 92 (78.0)                             | 26 (22.0)                             | 1.94 (1.11 to 3.32); P=0.017     | 1.91 (1.07 to 3.34); P=0.025     |
| Any comorbidity:          |                                       |                                       |                                 |                                 |
| No/unknown                | 305 (85.2)                            | 53 (14.8)                             | -                               | -                               |
| Yes                       | 210 (76.9)                            | 63 (23.1)                             | 1.73 (1.15 to 2.60); P=0.008     | 1.42 (0.89 to 2.28); P=0.141     |

1 Univariable and multivariable logistic regression analyses used potential predictors identified a priori and during exploratory analyses.
Table 5 | Demographics at presentation and therapies administered stratified by multisystem inflammatory syndrome in children and adolescents (MIS-C) status. Values are numbers (percentage) unless stated otherwise

| Variable                                                | Did not meet MIS-C criteria (n=404; 88.6%) | Met MIS-C criteria (n=52; 11.4%) | P value* |
|---------------------------------------------------------|------------------------------------------|----------------------------------|----------|
| Median (interquartile range) age, years                 | 1.6 (0.2 to 12.9)                       | 10.7 (3.1 to 14.1)              | <0.001   |
| Age group, years:                                       |                                          |                                  |          |
| <1                                                      | 164 (40.6)                               | 1 (1.9)                          |          |
| 1-4                                                     | 70 (17.3)                                | 4 (7.7)                          |          |
| 5-9                                                     | 43 (10.6)                                | 16 (30.8)                        |          |
| 10-14                                                   | 48 (11.9)                                | 22 (42.3)                        |          |
| 15-19                                                   | 79 (19.6)                                | 9 (17.3)                         |          |
| Sex at birth:                                           |                                          |                                  | 1.00     |
| Male                                                    | 241 (59.7)                               | 31 (59.6)                        |          |
| Female                                                  | 163 (40.3)                               | 21 (40.4)                        |          |
| Missing                                                 | 0 (0.0)                                  | 0 (0.0)                          |          |
| Ethnicity:                                              |                                          |                                  | 0.004    |
| White                                                   | 207 (51.2)                               | 16 (30.8)                        |          |
| Black                                                   | 30 (7.4)                                 | 9 (17.3)                         |          |
| South Asian                                             | 44 (10.9)                                | 4 (7.7)                          |          |
| Other                                                   | 74 (18.3)                                | 16 (30.8)                        |          |
| Missing                                                 | 49 (12.1)                                | 7 (13.5)                         |          |
| White ethnicity:                                        |                                          |                                  | 0.004    |
| No                                                      | 148 (36.6)                               | 29 (55.8)                        |          |
| Yes                                                     | 207 (51.2)                               | 16 (30.8)                        |          |
| Missing                                                 | 49 (12.1)                                | 7 (13.5)                         |          |
| Any comorbidity:                                        |                                          |                                  | 0.052    |
| No                                                      | 227 (56.2)                               | 37 (71.2)                        |          |
| Yes                                                     | 177 (43.8)                               | 15 (28.8)                        |          |
| Obesity:                                                |                                          |                                  | 0.005    |
| No                                                      | 379 (93.8)                               | 46 (88.5)                        |          |
| Yes                                                     | 6 (1.5)                                  | 5 (9.6)                          |          |
| Missing                                                 | 19 (4.7)                                 | 1 (1.9)                          |          |
| Immunosuppressant use before presentation†:            |                                          |                                  | 0.60     |
| No                                                      | 348 (86.1)                               | 48 (92.3)                        |          |
| Yes                                                     | 35 (8.7)                                 | 3 (5.8)                          |          |
| Missing                                                 | 21 (5.2)                                 | 1 (1.9)                          |          |
| Admitted >5 days before symptom onset:                 |                                          |                                  | 0.014    |
| No                                                      | 345 (85.4)                               | 52 (100.0)                       |          |
| Yes                                                     | 55 (8.7)                                 | 0 (0.0)                          |          |
| Missing                                                 | 24 (5.9)                                 | 0 (0.0)                          |          |
| Intravenous steroid:                                    |                                          |                                  | <0.001   |
| No                                                      | 333 (82.4)                               | 20 (38.5)                        |          |
| Yes                                                     | 20 (5.0)                                 | 24 (46.2)                        |          |
| Missing                                                 | 51 (12.6)                                | 8 (15.4)                         |          |
| High flow nasal cannula oxygen:                         |                                          |                                  | <0.001   |
| No                                                      | 343 (84.9)                               | 29 (55.8)                        |          |
| Yes                                                     | 47 (11.6)                                | 23 (44.2)                        |          |
| Missing                                                 | 14 (3.5)                                 | 0 (0.0)                          |          |
| Non-invasive ventilation:                               |                                          |                                  | <0.001   |
| No                                                      | 366 (90.6)                               | 34 (65.6)                        |          |
| Yes                                                     | 31 (7.7)                                 | 18 (34.6)                        |          |
| Missing                                                 | 7 (1.7)                                  | 0 (0.0)                          |          |
| Invasive ventilation:                                   |                                          |                                  | 0.001    |
| No                                                      | 361 (89.4)                               | 38 (73.1)                        |          |
| Yes                                                     | 36 (8.9)                                 | 14 (26.9)                        |          |
| Missing                                                 | 7 (1.7)                                  | 0 (0.0)                          |          |
| Inotropic support:                                      |                                          |                                  | <0.001   |
| No                                                      | 362 (89.6)                               | 24 (46.2)                        |          |
| Yes                                                     | 18 (4.5)                                 | 25 (48.1)                        |          |
| Missing                                                 | 24 (5.9)                                 | 3 (5.8)                          |          |
| ICU/HDU admission:                                      |                                          |                                  | <0.001   |
| No                                                      | 342 (84.7)                               | 14 (26.9)                        |          |
| Yes                                                     | 62 (15.3)                                | 38 (73.1)                        |          |
| Missing                                                 | 0 (0.0)                                  | 0 (0.0)                          |          |
| Outcome:                                                |                                          |                                  | 0.49     |
| Died                                                    | 4 (1.0)                                  | 0 (0.0)                          |          |
| Discharged alive                                        | 353 (87.4)                               | 47 (88.3)                        |          |
| Ongoing care                                            | 37 (9.2)                                 | 8 (15.4)                         |          |
| Palliative discharge                                    | 2 (0.5)                                  | 0 (0.0)                          |          |
| Missing                                                 | 8 (2.0)                                  | 1 (1.9)                          |          |

*HDU=high dependency unit; ICU=intensive care unit.
*Categorical variables analysed using Fisher’s exact test and continuous variables by Kruskal-Wallis test.
†Includes oral but not inhaled corticosteroids.
Strengths and limitations of study

This study is unique in that data for patients with laboratory confirmed covid-19 were collected prospectively and throughout the admission. The ISARIC WHO CCP-UK study had previously been activated in 2016 and 2018 for cases of Middle East respiratory syndrome (MERS) and monkeypox, and so was prepared for the SARS-CoV-2 pandemic, allowing swift activation. Consequently, in addition to reporting the clinical characteristics, risk factors, and outcomes of covid-19 in children, this dataset provided a unique opportunity to objectively monitor the emergence and progression of a novel multisystem inflammatory syndrome in the UK, while minimising recall bias.

The first patient meeting the criteria for MIS-C was identified on 20 March 2020, and the first published cases were reported on 6 May 2020. Comparison with overall covid-19 cases confirms the sporadic occurrence of MIS-C throughout the first peak of the covid-19 pandemic in the UK. In contrast to previous reports, our analysis was limited to children admitted with laboratory confirmed SARS-CoV-2, which allowed us to clearly define the picture of covid-19 in children and reduce confounding by other potential causes.

The ISARIC WHO CCP-UK database was estimated to represent two thirds of hospital admissions for covid-19 across England, Wales, and Scotland at the time of extraction. It is therefore susceptible to selection bias, particularly as tertiary centres with critical care units and specialist children’s hospitals are more likely to have dedicated research teams, potentially skewing the severity and age of the patients reported. The most common presenting symptoms in children in our study (fever, cough, and dyspnoea) reflect the original case definition for SARS-CoV-2 testing in the UK, suggesting that this paediatric cohort is likely to have been influenced by the testing criteria.

The PEWS is validated up to 16 years of age. As ranges of clinical observations do not vary much between 16 and 18 year olds, PEWS scoring was extended to all those under 19 years. To identify children and young people meeting the WHO criteria for MIS-C, data on C reactive protein and fever are needed. Decisions to measure C reactive protein and other parameters were at physicians’ discretion. Children missing either of these variables were excluded from this analysis.

A limitation of this study is the use of a case record form that was agnostic to age and so not specifically tailored for paediatric data collection, particularly regarding comorbidities. Some of this information was available in free text, but these data were incomplete. By design, we were not able to differentiate between people whose symptoms were directly attributable to SARS-CoV-2 infection and those who had been admitted for other reasons and then found to be positive for the virus. The study relied primarily on polymerase chain reaction testing as evidence of SARS-CoV-2 infection, as diagnostic serology was not available at the start of the pandemic. This could have limited early recruitment of MIS-C cases. Finally, in order to share findings from this study promptly as an urgent public health research priority, these analyses were performed on a cohort with ongoing data collection and missing data, the proportion of which will decrease with time. This may affect our estimate of the incidence of MIS-C at 11% (52/456) among children and young people with proven SARS-CoV-2 infection, which is calculated on the 70% (456/651) who had data available for fever and C reactive protein, thus allowing WHO preliminary criteria to be applied. Children without features of MIS-C or sepsis are not likely to have their clotting and inflammatory markers measured, so reducing the pool of complete data and the denominator. We do not have data for children identified as infected with SARS-CoV-2 in the community who were not admitted to hospital, and we cannot yet report on sequelae of covid-19 in children after discharge.

Comparison with other studies

Children and young people aged under 19 years accounted for 0.9% (651/69 516) of the ISARIC WHO CCP-UK cohort on 3 July 2020, which is broadly consistent with 2% reported in China and 1.7% in North America. Our cohort of paediatric patients admitted to hospital had a median age of 4.6 years,
which was similar to an Italian cohort (3.3 years), but younger than Chinese (6-7 years) and North American (11 years) cohorts; however, these other cohorts were not limited to children admitted to hospital. Although respiratory presentations were most common, 35% of children also had gastrointestinal symptoms at presentation, which is higher than the 10-22% reported in other paediatric literature.2, 21, 22 Gastrointestinal symptoms have also been prominent in children presenting with infection by MERS-CoV (28%) and severe acute respiratory syndrome coronavirus (SARS-CoV) (30%).23, 24 We also identified a distinct systemic mucocutaneous-enteric cluster of symptoms in the acute phase of SARS-CoV-2 infection, which shows overlap with the WHO preliminary case definition for MIS-C.

Children of black ethnicity were over-represented, comprising 10% of our paediatric cohort compared with a population representation of 4.7% of all children under 18 years across England and Wales and 1% in Scotland.25, 26 This finding may also be influenced by the ethnic composition of the population served by the sites recruiting to this study. Black ethnicity was also associated with increased odds of admission to critical care on multivariable analysis, consistent with reports for adult populations suggesting that South Asian and black ethnicities are disproportionately severely affected by SARS-CoV-2 infection.27-29 Studies of paediatric covid-19 from other countries either have been from ethnically homogenous groups or have not reported ethnicity, making comparisons difficult.

The rate of admission to critical care in our cohort was 18%, compared with 10% reported in a North American cohort of children admitted to hospital and 13% in a multicentre cohort study across 25 European countries.2, 22 As previously noted, this rate may be elevated in our study owing to hospitals with dedicated paediatric research teams being more likely to provide paediatric critical care. The prevalence of comorbidities (54%) in children admitted to critical care in our cohort was also similar to that reported in the European multicentre study (52%).22 Obesity was associated with critical care admission in our paediatric cohort, in agreement with adult data from ISARIC WHO CCP-UK.13 In England, 20% of children are obese by 11 years of age.30 Childhood obesity, however, is also influenced by deprivation,30 which we did not analyse in our study. Age under 1 month was associated with increased odds of critical care admission, in agreement with the European cohort.22 Thirty five per cent of children in our study were under 1 year old, which may reflect a low threshold for admissions of infants by clinicians rather than severe concerns about their clinical condition. This may explain the predominance of younger children in our study. In addition, the association between age under 1 month and admission to critical care might be explained if these babies were already admitted to neonatal intensive care and undergoing regular SARS-CoV-2 screening.

Using adapted WHO criteria,9 we identified 52 patients meeting the criteria for multisystem inflammatory syndrome. Initial UK reports described children admitted to hospital with circulatory shock and a hyperinflammatory state with features similar to toxic shock or Kawasaki disease.8 Children fulfilling the case definition for MIS-C have been reported in multiple regions experiencing large outbreaks of covid-19, including England (UK),11 Paris (France),11 Bergamo (Italy),10 and New York City (USA).12 Ours is the first report, however, to identify cases and timelines by using a prospective national data collection strategy. MIS-C seems to be temporally associated with covid-19, but a causal relation remains to be established. Older age and non-white ethnicity were associated with MIS-C in our study, in agreement with a recent case series of 99 children with MIS-C from New York State (USA), where 63% were of non-white ethnicity and 69% were aged between 6 and 20 years.12 Children in our study with MIS-C were much more unwell than other children with covid-19, with 51% needing inotropic support, compared with 20% in the Italian cohort,10 47% in the French cohort,11 and 62% in the New York cohort.29

It is becoming apparent that MIS-C can present both in children with acute SARS-CoV-2 infection and in the post-acute or convalescent phase of infection. A large case series of 565 children with MIS-C across North America has been recently reported by the Centers for Disease Prevention and Control (CDC), which used latent class analysis to identify three classes of MIS-C.33 Class 1 predominantly comprises patients who were antibody positive and polymerase chain reaction negative for SARS-CoV-2, with multiple systems involved, a strong association with cardiac complications, and a greater likelihood of having received intravenous immunoglobulin and corticosteroids. These class 1 patients resemble the post-acute group in our analysis. The CDC describes class 2 as children who were predominantly polymerase chain reaction positive for SARS-CoV-2, with inflammation involving, a strong association with cardiac complications, and a greater likelihood of having received intravenous immunoglobulin and corticosteroids. These class 1 patients resemble the acute group in our analysis.

We believe that the characterisation of SARS-CoV-2 illness in children into polymerase chain reaction positive versus serology positive as distinct entities is likely to be an oversimplification. Instead, our data suggest that clinical presentation varies at different time points in the course of SARS-CoV-2 infection and immune response. Across the whole of our paediatric cohort, we identified a distinct cluster presenting with systemic mucocutaneous-enteric symptoms (rash, conjunctivitis, diarrhoea, vomiting, and abdominal pain) in addition to headache, myalgia, sore throat, fatigue, and lymphadenopathy, which overlapped closely with the WHO preliminary case definition.9

MIS-C can present in both the acute and convalescent phases of SARS-CoV-2 infection. The significant associations between MIS-C and fatigue, headache, myalgia, sore throat, and lymphadenopathy in our cohort may be useful in refining the case definition.
In addition, the association of MIS-C with platelet count less than 150×10^9/L and low lymphocyte counts agrees with previous reports. These important findings may assist in differentiating this syndrome from other illnesses, particularly Kawasaki disease in which platelet counts are typically elevated.

**Conclusion and policy implications**

Our data confirm less severe covid-19 in children and young people with SARS-CoV-2 infection than in adults. Admission to critical care was associated with age under 1 month, age 10-14 years, and black ethnicity. In agreement with previous reports, we found older age and non-white ethnicity to be associated with MIS-C.

We also report that patients with MIS-C who are antibody positive for SARS-CoV-2 are more likely to be of non-white ethnicity, have mucocutaneous-nerve symptoms and cardiac complications, and have received intravenous immunoglobulins and corticosteroids than those who are in the acute phase of infection (polymerase chain reaction positive).

We have identified a systemic mucocutaneous-nerve symptom cluster across the whole cohort. In addition, we have provided evidence for refining the WHO case definition for MIS-C, including an association with low platelet count, fatigue, headache, myalgia, sore throat, and lymphadenopathy.

**AUTHOR AFFILIATIONS**

1Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
2Royal Hospital for Sick Children, Paediatric Infectious Diseases, Edinburgh, UK
3Women’s and Children’s Health, Institute of Translational Medicine, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
4Respiratory Medicine, Alder Hey Children’s NHS Foundation Trust, Liverpool L1 2 ZAP, UK
5Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
6Infectious diseases Unit, Royal Liverpool University Hospital, Liverpool, UK
7Paediatric Infectious Diseases, Royal Hospital for Children, Glasgow, UK
8Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK
9Institute for Adaptive and Neural Computation, School of Informatics, University of Edinburgh, UK
10Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
11Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
12Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK
13Immunisation and Countermeasures Division, Public Health England, London, UK
14Paediatric Infectious Disease, St George’s Hospital, London, UK
15SARIc Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
16Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK
17United Kingdom Department of Health and Social Care, London, UK
18National Infection Service, Public Health England, [A: Where?] uk
19National Heart and Lung Institute, Imperial College London, London, UK

20Roslin Institute, University of Edinburgh, Edinburgh, UK
21Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK

This work uses data provided by patients and collected by the NHS as part of their care and supports #DataSavesLives. We are extremely grateful to the 2648 frontline NHS clinical and research staff and volunteer medical students who collected this data in challenging circumstances and for the generosity of the participants and their families for their individual contributions in these difficult times. We also acknowledge the support of Jeremy Farrar, Nahoko Shindo, Devika Dast, Nupnie Rajaapake, Lyndsey Castle, Martha Buckley, Debbie Malden, Katherine Newell, Kwanne O’Neil, Emilienne Denis, Claire Petersen, Scott Mullaney, Sue MacFarlane, Nicole Maziere, Emil Cas, Krishanthi S Subramaniam, Julien Martinez, Oseim Dincarslan, and Annette Lake. The study protocol is available at https://isaric4c.net/protocols, study registry https://www.isrctn.com/ISRCTN66726260.

ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4CC) Investigators: Consortium lead investigator: J Kenneth Baillie; chief investigator: Malcolm G Semple. Co-lead investigator: S Andrew Trocha. Co-investigators: Beatrice Alex, Benjamin Bach, Wendy S Barclay, Debby Bogaert, Meera Chand, Graham S Cooke, Annemarie B Docherty, Jake Dunnng, Ana da Silva Filipe, Tom Fletcher, Christopher A Green, Ewen M Harrson, Julian A Hiscos, Antonia Ying Wai Ho, Peter W Horby, Samreen Ijaz, Saye Khoo, Paul Klee, Andrew Law, Wei Shen Lim, Alexander J Mentrez, Laura Merson, Alison M Meynet, Mahdad Noursadeghi, Shona C Moore, Massimo Palmirini, William A Paxton, Georgios Pollakis, Nicholas Price, Andrew Rambaut, David L Robertson, Clark D Russell, Vanessa Sancho-Shimizu, Janet T Scott, Louise Sigfrid, Tom Solomon, Shimon Sridkanan, David Stuart, Charlotte Summers, Richard S Tedder, Emma C Thomson, Ryan S Thwaites, Lance C W Turtle, Maria Zambon; project managers: Hayley Hardwick, Chloe Donohue, Jane Ewins, Wilna Oosthuysen, Fiona Griffiths. Data analysts: Lisa Norman, Riian Pi, Tom M Drake, Cameron J Fairfie, Stephen Knight, Kenneth M Mclean, Derek Murphy, Catherine A Shaw. Data and information system managers: Jo Dalton, Michelle Girvan, Egle Savigiene, Stephanie Roberts, Janet Harrison, Laura Marsh, Marie Connor, Sophie Halpin, Clare Jackson, Carrol Gamble. Data integration and presentation: Gary Leenin, Andrew Law, Ross Hendy. Materal management: William Greenhalf, Victoria Shaw, Sarah McDonald. Outbreak laboratory volunteers: Katie A Ahmed, Jane A Armstrong, Milton Ashworth, Innocent G Asimwe, Siddharth Bakshe, Samantha L Barlow, Laura Booth, Benjamin Brennan, Katie Bullock, Benjamin W A Catterall, Jordan J Clark, Emily A Clarke, Sarah Cole, Louise Cooper, Helen Cox, Christopher Davis, Oslem Dincarslan, Chris Dunn, Philip Dyer, Angelina Elliott, Anthony Evans, Lewis W S Fisher, Terry Foster, Isabel Garcia-Dorval, William Greenhalph, Philip Gunnning, Catherine Hartley, Antonia Ha, Rebecca L Jensen, Christopher B Jones, Trevor R Jones, Shadia Khandaker, Katharine King, Robyn T Kiy, Chrysa Koukorava, Annette Lake, Suzanne Lant, Diane Latawiec, Lavelle-Langham, Daniella Letferi, Lauren Lett, Lucia A Livot, Maria Mancini, Sarah McDonald, Laurence McEvoy, John Mclauchlan, Suiren Mettelman, Nahida S Mah, Joanna Middleton, Joyce Mitchell, Shona C Moore, Ellen G Murphy, Rebekah Penrice-Randal, Jack Pilgrim, Tessa Prince, William Reynolds, P Matthew Ridley, Debby Sales, Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanthi S Subramaniam, Agnieska Szemiel, Asilmy Taggart, Jolanta Tainaris, Jordan Thomas, Erwan Trochu, Libby van Tonder, Eve Wilcock, J Enice Zewdie. Local principal investigators: Kayode Adeniin, Daniel Agranooff, Ken Agwu, Dhiraj AI, Ana Alegra, Brian Angus, Abdul Ashish, Dougall Atkinson, Shahedal Ban, Gavin Barlow, Stella Bamass, Nicholas Barrett, Christopher Bassford, David Baxter, Michael Beadsworth, Jolanta Bennamotienie, John Benendge, Nicola Bestley, Pieter Bothma, David Brealey, Robin Brittain-Long, Naomi Bultee, Tom Burden, Andrew Buttenshaw, Vikki Caruth, David Chadwick, Duncan Chambler, Nigel Chee, Jenny Child, Srinath Chakkambotta, Tom Clark, Paul Collins, Catherine Cosgrove, Jason Cuppet, Maria-Teresa Cuthbert-Moguel, Paul Dark, Chris Dawson, Samir Dervisovic, Phil Donginn, Sam Douthwaite, Ingrid DuRand, Ashlundran Dushanthan, Tristan Dyer, Caniad Evans, Chi Eziefula, Christopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev Garg, Sanjeev Garg, Atul Garg, Jo Godden, Arthur Goldsmith, Olve Graham, Elaine Hardy, Stuart Hartshorn, Daniel Harvey, Peter Havalda, Daniel B Hawcutt, Maria Hubrok, Luke Hodgson, Anita Holme, Anil Homris, Michael Jacobs, Susan Jain, Paul Jennings, Agilan Kaliappan, Vidya Kasipandin, Stephen Kegg, Michael Kelsey, Jason Kendall, Caroline Kernson, Ian Kerslake, Oliver Koc, Gouri Koduri, George Koshy, Shondipon Laha, Susan Larkins, Tamis Leiner, Patrick Lillei,
James Limb, Vanessa Linnett, Jeff Little, Michael MacMahon, Emily MacNaughton, Ravish Mankregod, Huw Masson, Elijah Matowo, Katherine McCullough, Ruth McEwen, Manjula Meda, Gary Mills, Jane Minton, Maryam Mirfenderesky, Kayava Mohandas, Quen Mok, James Moon, Elinoor Moore, Patrick Morgan, Craig Morris, Katherine Mortimore, Samuel Moses, Mbuye Mpenge, Rohinton Mulla, Michael Murphy, Megan Nagel, Thapass Nagarajan, Mark Nelson, Igor Otahal, Mark Paix, Selva Panchatsharam, Hassan Parasoo, Brij Patel, Justin Pepperell, Mark Peters, Mandeep Philli, Stefania Pintus, Jagtir Singh Pooni, Frank Post, David Price, Rachel Poult, Nikolaes Rae, Henrik Resche-Timmer, Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, Alistair Rose, Guy Rousseaux, Brendan Ryan, Taranpreet Saluja, Aarti Shah, Prad Shannug, Ani Sharma, Anna Shawcross, Jeremy Sizer, Richard Smith, Katherine Snelson, Nick Spittle, Nikkie Staines, Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakszmany, Kate Tatham, Jo Thomas, Chris Thompson, Robert Thompson, Ascario Tridente, Darel Tupper-Carey, May Twagaria, Andrew Ustianowski, Nick Vallotton, Lisa Vincent-Smith, Shico Visvanathan, Alan Vuyisjeke, Sam Waddy, Rachel Wake, Andrew Walden, Ingeborg Weiters, Tony Whitehouse, Paul Whitaker, Ashley Whittington, Meme Wjesingehe, Martin Williams, Lawrence Wilson, Sarah Wilson, Stephen Winchester, Martin Wiselka, Adam沃尔ver, Daniel G Wooton, Andrew Workman, Bryan Yates, Peter Young.

Contributors: OVS, KA, LS, PL, JSN-V-T, PHW, LM, GC, WD, PIMO, JKB, EMB, ABD, and MGS developed the concept of the study. SH, MG, LM, EMB, and ABD were responsible for data curation. OVS, LPO, CT, TMD, SS, CE, MGP SL, IP, PHW, LM, EMB, and ABD managed the data (JSN-V-T, PHW, GC, PIMO, JKB, ABD, and MGS obtained funding. OVS, KA, LT, LP SL, EMB, and ABD were involved in investigation. OVS, KA, LT, LPO, SL, EMB, ABD, and MDS developed the methodology. KA, LT, HH, SH, MG, CD, LPS, LS, and LM were responsible for administration. LS, PO, PHW, LM, and MGS coordinated resources. OVS, CF, TMD, SS, CE, and LM developed software. HH, SL, PO, JSN-V-T, LM, PIMO, JKB, ABD, and MGS provided supervision. KA, LT, and LPO validated the data. OVS, CF, TMD, SS, CE, MGP, EMB, and ABD were involved in data visualisation. OVS, KA, LT, LPO, SL, EMB, ABD, and MGS wrote the original draft of the manuscript. OVS, KA, LT, LPO, CF, TMD, MGP, LPA, SL, PSI, JSN-V-T, JKB, EMB, ABD, and MGS reviewed and edited the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. MGS is the guarantor.

Funding: This work is supported by grants from the National Institute for Health Research (award CO-CIN-01) and the Medical Research Council (grant MC_PC_190159) and by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 2009907). Welcome Trust and Department for International Development (215091/12/18/2), and the Bill and Melinda Gates Foundation (OPP1001935). Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research (grant reference: C18616/A25153). JSN-V-T is seconded to the Department of Health and Social Care, England (DHSC). The views expressed are those of the authors and not necessarily those of the DHSC, Did, NIHR, MRC, Wellcome Trust, or PHE.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/col_disclosure.pdf and declare: support from the National Institute for Health Research and the Medical Research Council; JSN-V-T received grants from the Department of Health and Social Care, England, during the conduct of the study; PHW received grants from the Wellcome Trust, Department for International Development, and Bill and Melinda Gates Foundation and from NIH during the conduct of the study; PIMO received personal fees from consultancy and grants from MRC, grants from EU Grant, grants from NIHR Biomedical Research Centre, grants from MRC/GSK, grants from Wellcome Trust, grants from NIHR (HPRU), grants from the European Respiratory Society, and grants from MRC Global Challenge Research Fund, outside the submitted work, and although the role of president of the British Society for Immunology was an unpaid appointment, travel and accommodation at some meetings is provided by the society; ABD received grants from Department of Health and Social Care, during the conduct of the study, and grants from Wellcome Trust outside the submitted work; JKB received grants from DHSC National Institute of Health Research UK, Medical Research Council UK, Wellcome Trust, Fiona Elizabeth Agnew Trust, Intensive Care Society, and Chief Scientist Office, during the conduct of the study; MGS received grants from DHSC National Institute of Health Research UK, Medical Research Council UK, and Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, during the conduct of the study, and from Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Ethical approval was given by the South Central - Oxford C Research Ethics Committee in England (ref 13/SC/0149), the Scotland A Research Ethics Committee (ref 05SS/0208), and the WHO Ethics Review Committee (RPC7/1 and RPC57/2, 25 April 2013).

Data sharing: The Independent Data and Material Access Committee welcomes applications for access to data and materials (https://isaric4c.net).

Transparency: The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: ISARIC4C has a public facing website and twitter account (@CCPUKstudy). We are engaging with print and internet press, television, radio, news, and documentary programme makers. We will explore distribution of findings with The Asthma UK and British Lung Foundation Partnership and take advice from NIHR Involve and GenerationAll Young People’s Advisory Groups.

Provenance and peer review: Not commissioned; externally peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited: see http://creativecommons.org/licenses/by/4.0/.

1 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323:1239-42. doi:10.1001/jama.2020.2648

2 CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:423-6. doi:10.15585/mmwr.mdr.201448

3 European Centre for Disease Prevention and Control. Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. 2020. https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment

4 Viner RM, Mytton OT, Bonell C, et al. Susceptibility to and transmission of COVID-19 among children and adolescents compared with adults: a systematic review and meta-analysis. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.05.20.20108161v1

5 Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19: An overview of 180 countries. Pediatr Infect Dis J. 2020;39:e20200702. doi:10.1542/peds.2020-0702

6 Lu X, Zhang L, Du H, et al, Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;392:1636-5. doi:10.1056/NEJM20201173

7 Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med. 2020;382:1370-1. doi:10.1056/NEJM20201173

8 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theoharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607-8. doi:10.1016/S0140-6736(20)31094-1

9 World Health Organization. Multisystem inflammatory syndrome in children associated with COVID-19. 2020. https://www.who.int/news-room/news-events/detail/multisystem-inflammatory-syndrome-in-children-associated-with-covid-19

10 Verdino L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771-8. doi:10.1016/S0140-6736(20)31103-X

11 Toubiana J, Pourrat C, Conia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094. doi:10.1136/bmj.m2094

12 Royal College of Paediatrics and Child Health. Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS). 2020. https://www.rcph.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims

13 Kocherly AB, Harrison EM, Green CA, et al, ISARIC4C investigators. Features of 2013 UK patients in hospital with covid-19 using
the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985. doi:10.1136/bmj.m1985

14 Healthcare Improvement Scotland. Paediatric Early Warning Score (PEWS) Charts. 2020. https://hub.scot/improvement-programmes/scottish-patient-safety-programme-ssp/maternity-and-children-quality-improvement-collaborative-mcqc/paediatric-care/pews/

15 Fischbach FT, Dunning MB. A manual of laboratory and diagnostic tests. Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009.

16 Arslan FD, Serdar M, Merve Ari E, et al. Determination of Age-Dependent Reference Ranges for Coagulation Tests Performed Using Destiny Plus. Iran J Pediatr 2016;26:e6177. doi:10.5812/ijp.6177

17 Toulon P, Berruyer M, Brionne-François M, et al. Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. Thromb Haemost 2016;116:9-16. doi:10.1160/TH15-12-0964

18 Williams MD, Chalmers EA, Gibson BES, Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematothology. The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol 2002;119:295-309. doi:10.1046/j.1365-2141.2002.03674.x

19 Lewis KM, Parekh SM, Ramnarayan P, Gilbert R, Hardelid P, Wijlaars L. Emergency paediatric critical care in England: describing trends using routine hospital data. Arch Dis Child 2020;archdischild-2019-317902. doi:10.1136/archdischild-2019-317902

20 Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet 2011;377:1011-8. doi:10.1016/S0140-6736(10)62226-X

21 Parri N, Lenge M, Buonsenso D, Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in Pediatric Emergency Departments in Italy. N Engl J Med 2020;383:187-90. doi:10.1056/NEJMoa2007617

22 Gotzinger F, Santiago-García B, Nogueira-Julían A, et al. pIbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020;4:653-61. doi:10.1016/S2352-4642(20)30177-2

23 Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Memish ZA. Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. Front Pediatr 2019;13:126-30. doi:10.1007/s11684-017-0603-y

24 Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003;361:1701-3. doi:10.1016/S0140-6736(03)13364-8

25 UK Government. UK population by ethnicity. Population statistics and 2011 Census data. Age groups. 2020. https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/demographics/age-groups/latest?age-profile-by-ethnicity.

26 Scotland’s Census. Ethnic group. 2018. https://www.scotlandscensus.gov.uk/variables-classification/ethnic-group.

27 Office for National Statistics. Coronavirus (COVID-19) related deaths by ethnic group, England and Wales. 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/coronavirusrelateddeathsbyethnicgroupenglandandwales/2march2020to10april2020.

28 Niedzwiedz C, O’Donnell CA, Jani BD, et al. Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.04.22.20075672v2.

29 Harrison EM, Docherty AB, Barr B, et al. Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. 2020. https://papers.ssm.com/abstract=3618215.

30 NHS Digital. National Child Measurement Programme, England - 2017/18 School Year [PAS]. 2018. https://digital.nhs.uk/data-and-information/publications/statistical/national-child-measurement-programme/2017-18-school-year.

31 Whittaker E, Bamford A, Kenny J, et al, PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 2020;323:1036-69. doi:10.1001/jama.2020.10369

32 Dufort EM, Koumans EH, Chow EJ, et al, New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 2020;383:347-58. doi:10.1056/NEJMoa2021756

33 Godfred-Cato S, Bryant B, Leung J, et al, California MIS-C Response Team. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020;69:1074-80. doi:10.15585/mmwr.mm6932e2

Web appendix: Supplementary material